Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b…
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Data spans seven presentations across both solid tumors and hematologic malignancies, providing…
Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
BASEL, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical…
NextCure and Simceres SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
The American Society for Clinical Oncology to be held in Chicago May…
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
February 23, 2026 17:10 ET | Source: Kyntra Bio FG-3246 and enzalutamide…
American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research
Global oncology society calls for abstract submissions for research that is shaping…
Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic…
Medidata Debuts Protocol Optimization at ASCO, Leveraging AI to Transform the Study Experience
New solution improves protocol design, reduces patient- and site-burden, accelerates recruitment, and…
